Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02149836 · ClinicalTrials.gov registry record · Phase 2
Study to Treat Major Depressive Disorder (MDD) With a New Medication
A Phase 2 study, sponsored by Icahn School of Medicine at Mount Sinai.
- Completed
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
NCT02149836 is a Phase 2 study that has completed, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 18 participants.
The verdict
NCT02149836, a Phase 2 study, has completed, sponsored by Icahn School of Medicine at Mount Sinai.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
Study Summary
The purpose of this study is to test the antidepressant effects of Ezogabine in major depressive disorder (MDD). The investigators also aim to determine the safety and tolerability Ezogabine in patients with MDD. The investigators hypothesize that depressive symptoms will be significantly decreased following an 8-week treatment period of the medication compared to baseline.
Interventions
- DRUG ezogabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2014-08 |
| Est. Completion | 2016-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02149836
The ClinicalTrials.gov registry entry for NCT02149836 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Icahn School of Medicine at Mount Sinai, which has 708 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ezogabine is the first listed.
NCT02149836 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02149836 about?
NCT02149836 is a clinical study titled "Study to Treat Major Depressive Disorder (MDD) With a New Medication". The purpose of this study is to test the antidepressant effects of Ezogabine in major depressive disorder (MDD). The investigators also aim to determine the safety and tolerability Ezogabine in patients with MDD. The investigators hypothesize that depressive symptoms will be significantly decreased ...
What is the current status of trial NCT02149836?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2014-08. Estimated completion is 2016-12.
What interventions are being tested in trial NCT02149836?
The interventions under investigation include: ezogabine (DRUG).
Who is sponsoring clinical trial NCT02149836?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.